<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02126124</url>
  </required_header>
  <id_info>
    <org_study_id>BR-SMOK-01</org_study_id>
    <nct_id>NCT02126124</nct_id>
  </id_info>
  <brief_title>Evaluation of Deep Transcranial Magnetic Stimulation (DTMS) With the H-ADD Coil as an Aid to Smoking Cessation.</brief_title>
  <official_title>A Prospective, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (DTMS) (With the H-ADD Coil) Intended as an Aid to Smoking Cessation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brainsway</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brainsway</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and efficacy of DTMS compared to sham
      treatment as an aid to smoking cessation in chronic, heavy (&gt;10 cigarettes/day) cigarette
      smokers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi center, randomized, double blind study to evaluate the safety and
      effectiveness of the device as an aid to smoking cessation. Treatment will be administered
      over a 6 week period and follow-up assessments will be conducted at 4 months. The clinical
      study design includes multiple measurements of safety and effectiveness parameters. The
      design is meant to demonstrate that the device shows superiority compared to sham treatment
      over six treatment weeks, at the 4 months follow up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuous Quit Rate</measure>
    <time_frame>4 week</time_frame>
    <description>The primary objective is to compare the four-week continuous quit rate (CQR), representing abstinence during a consecutive 4 week period during the treatment phase, between the two treatment groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Cigarettes Smoked Per Day</measure>
    <time_frame>4 Weeks</time_frame>
    <description>The secondary objective is to compare number of cigarettes smoked per day (per diary data) for all subjects.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Long term CQR</measure>
    <time_frame>4 Months</time_frame>
    <description>Long-term continuous quit rates (CQR) at four months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Withdrawal Symptoms</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Effect on withdrawal symptoms as measured by weekly scales measuring nicotine craving and dependence/withdrawal, including Fagerstrom Test for Nicotine Dependence (FTND), Minnesota Nicotine Withdrawal Scale Self-Report (MNWS), Tobacco Craving Questionnaire-Short Form (TCQ-SF) and Nicotine Craving Scale.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Active dTMS Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brainsway Deep TMS Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Brainsway Sham Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Treatment</intervention_name>
    <description>In the sham treatment, the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the the brain.</description>
    <arm_group_label>Sham Treatment</arm_group_label>
    <other_name>Brainsway Sham Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active dTMS Treatment</intervention_name>
    <description>Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The Brainsway Coil is a novel dTMS coil desigend to allow deeper brain stimulation without significant increase of electric fields induced in superficial cortical regions.</description>
    <arm_group_label>Active dTMS Treatment</arm_group_label>
    <other_name>Brainsway Deep TMS Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects, 22-70 years old.

          -  Chronic, heavy (&gt;10 cigarettes/day) smokers, who smoke for more than 1 year, with no
             period of abstinence for greater than 3 months during the past year.

          -  Subjects who are motivated to quit smoking (with responses &quot;very likely,&quot; or &quot;somewhat
             likely&quot; to the motivation questionnaire).

          -  Satisfactory answers on safety screening questionnaire for transcranial magnetic
             stimulation (Keel 2001).

          -  Gave informed consent for participation in the study.

        Exclusion Criteria:

          -  Currently on Nicotine Replacement Therapy (NRT) or smoking cessation drugs (e.g.,
             Zyban, Chantix, etc.) or undergoing behavioral smoking cessation interventions

          -  Cognitive or functional disability, diagnosed according to DSM-IV-TR criteria.

          -  Active psychiatric disorder according to DSM IV (Axis I and Axis II) criteria within
             the last year.

          -  Current alcohol or other substance abuse or dependence.

          -  Alcohol or other substance abuse or dependence during the last 12 months before
             recruitment.

          -  Subject is smoking any other form of tobacco or other substances.

          -  Subject is taking psychotropic medications on a regular basis.

          -  Subjects with a high risk for severe violence or suicidality as assessed during the
             screening interview.

          -  Subjects who suffer from an unstable physical disease such as high blood pressure
             (&gt;150 mmHg systolic / diastolic &gt; 110 mmHg) or acute, unstable cardiac disease.

          -  History of epilepsy or seizure (EXCEPT those therapeutically induced by ECT).

          -  Increased risk of seizure for any reason, including prior diagnosis of increased
             intracranial pressure (such as after large infarctions or trauma), or history of
             significant head injury or trauma with loss of consciousness for &gt; 5 minutes.

          -  History of any metal in the head (outside the mouth).

          -  Metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines,
             implanted neurostimulators, intracranial implant (e.g., aneurysm clips, shunts,
             stimulators, cochlear implants, or electrodes) or implanted medical pumps.

          -  Individuals with a significant neurological disorder or insult including, but not
             limited to:

               -  Any condition likely to be associated with increased intracranial pressure

               -  Space occupying brain lesion

               -  History of cerebrovascular accident

               -  Transient ischemic attack within two years

               -  Cerebral aneurysm

               -  Dementia

               -  Mini Mental State Exam score of less than or equal to 24

               -  Parkinson's disease

               -  Huntington's chorea

               -  Multiple sclerosis

          -  Subjects suffering from frequent and severe migraine headaches.

          -  Subjects suffering from significant hearing loss.

          -  Subjects taking pro-convulsant medications (e.g., antidepressants or antipsychotic
             medications).

          -  Previous treatment with TMS.

          -  Subjects who cannot communicate reliably with the investigator or who are not likely
             to cope with the requirements of the experiment.

          -  Participation in a clinical trial within the last 30 days before the beginning of this
             clinical trial or similar participation in another clinical trial.

          -  Known or suspected pregnancy or lactation.

          -  Women of childbearing potential and not using a medically accepted form of
             contraception when engaging in sexual intercourse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark George, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abraham Zangen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soroka University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen Brady, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hagar Moshe</last_name>
    <phone>972-523845102</phone>
    <email>hagarmo@Brainsway.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amit Ginou</last_name>
    <phone>972-526051372</phone>
    <email>amit@Brainsway.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pacific Institute of Medical Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Fosteson, Bc</last_name>
      <phone>310-208-7144</phone>
      <email>cfosteson@pacificmedresearch.com</email>
    </contact>
    <investigator>
      <last_name>Tanya Vapnik, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Schaffner</last_name>
      <phone>619-543-5978</phone>
      <email>nschaffner@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>David Feifel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TMS Center of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Stephenson</last_name>
      <phone>303-884-3867</phone>
      <email>claire@tmscenterofcolorado.com</email>
    </contact>
    <investigator>
      <last_name>Theodore Wirecki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Mason</last_name>
      <phone>352-273-8540</phone>
      <email>dmason@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Herbert Ward, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Mental Health Care Inc. - Juno Beach</name>
      <address>
        <city>Juno Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyssa Sisko</last_name>
      <phone>561-333-8884</phone>
      <email>elyssasisko@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aron Tendler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Mental Health Care Inc. - Royal Palm Beach</name>
      <address>
        <city>Royal Palm Beach</city>
        <state>Florida</state>
        <zip>33411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyssa Sisko</last_name>
      <phone>561-333-8884</phone>
      <email>elyssasisko@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aron Tendler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLean Hospital - TMS Services</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premier Psychiatric Group</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Espenschade</last_name>
      <phone>402-476-6060</phone>
      <email>kespenschade@premierpsych.com</email>
    </contact>
    <investigator>
      <last_name>Walter J Duffy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Psychiatric Group</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Espenschade</last_name>
      <phone>402-476-6060</phone>
      <email>kespenschade@premierpsych.com</email>
    </contact>
    <investigator>
      <last_name>Walter J Duffy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University / New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Grassetti</last_name>
      <phone>646-774-7654</phone>
      <email>grasset@nyspi.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dinnisa Chang</last_name>
      <phone>646-7747654</phone>
      <email>changdi@nyspi.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ned Nunes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lindner Center of HOPE, University of Cinicnnati College of Medicine</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Guerdjikova</last_name>
      <phone>513-536-0721</phone>
      <email>anna.guerdjikova@lindnercenter.org</email>
    </contact>
    <investigator>
      <last_name>John Hawkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jkeonye Moss</last_name>
      <phone>843-876-5141</phone>
      <email>mosjk@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Mark George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Senior Adults Specialty Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith Draper, Ph.D</last_name>
      <phone>512-407-8628</phone>
      <email>mdraper@senioradults.net</email>
    </contact>
    <investigator>
      <last_name>Jaron L. Winston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Addiction and Mental Health (CAMH)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mawahib Semeralul</last_name>
      <phone>416 535 8501</phone>
      <phone_ext>6434</phone_ext>
      <email>Mawahib.Semeralul@camh.ca</email>
    </contact>
    <investigator>
      <last_name>Daniel Blumberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lihi Bokovza</last_name>
      <phone>972-52-8512367</phone>
      <email>Lihi.bokovza@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Abraham Zangen</last_name>
    </contact_backup>
    <investigator>
      <last_name>Doron Toder</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abraham Zangen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beer Yaacov Mental Health Center</name>
      <address>
        <city>Beer Yaacov</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dikla Shmuel, MD</last_name>
      <phone>972-54-2494688</phone>
      <email>dikla.shmuel@moh.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Yehiel Lefkovitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lev Hasharon</name>
      <address>
        <city>Netanya</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Germany</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2014</study_first_submitted>
  <study_first_submitted_qc>April 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2014</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brainsway, dTMS, Deep Transcranial Magnetic Stimulation, Smoking Cessation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

